Company / Operating Income
Barinthus Biotherapeutics plc. Operating Income History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$70.6M
FY2025
5-year range
-$83.9M / -$4.0M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 5 years, ranging from -$84M in FY2024 to -$4M in FY2023.
Based on SEC 10-K filings.
-$71M in FY2025.
Declined from -$4M to -$71M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 15.9% year-over-year.
- Peak operating income was recorded in FY2023.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$70.6M | +15.9% |
| FY2024 | -$83.9M | -1976.6% |
| FY2023 | -$4.0M | +91.1% |
| FY2022 | -$45.2M | -125.6% |
| FY2021 | -$20.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026